Title: Cilengitide in newly diagnosed glioblastoma: biomarker expression and outcome.
Journal: Oncotarget 20160322
Title: Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, phase 3 trial.
Journal: The Lancet. Oncology 20140901
Title: Integrin inhibitor cilengitide for the treatment of glioblastoma: a brief overview of current clinical results.
Journal: Anticancer research 20121001
Title: Cilengitide in bevacizumab-refractory high-grade glioma: two case reports and critical review of the literature.
Journal: Anti-cancer drugs 20120801
Title: A randomized phase II study of cilengitide (EMD 121974) in patients with metastatic melanoma.
Journal: Melanoma research 20120801
Title: Cyclic RGD peptidomimetics containing bifunctional diketopiperazine scaffolds as new potent integrin ligands.
Journal: Chemistry (Weinheim an der Bergstrasse, Germany) 20120514
Title: Is there a world beyond bevacizumab in targeting angiogenesis in glioblastoma?
Journal: Expert opinion on investigational drugs 20120501
Title: A phase I study of continuous infusion cilengitide in patients with solid tumors.
Journal: Investigational new drugs 20120401
Title: Phase II study of cilengitide (EMD 121974, NSC 707544) in patients with non-metastatic castration resistant prostate cancer, NCI-6735. A study by the DOD/PCF prostate cancer clinical trials consortium.
Journal: Investigational new drugs 20120401
Title: Peptides for cell-selective drug delivery.
Journal: Trends in pharmacological sciences 20120401
Title: Anti-angiogenic approaches to malignant gliomas.
Journal: Current cancer drug targets 20120301
Title: Cilengitide in patients with recurrent glioblastoma: the results of NABTC 03-02, a phase II trial with measures of treatment delivery.
Journal: Journal of neuro-oncology 20120101
Title: Antiangiogenic therapy for patients with recurrent and newly diagnosed malignant gliomas.
Journal: Journal of oncology 20120101
Title: Targeting the tumor microenvironment: focus on angiogenesis.
Journal: Journal of oncology 20120101
Title: Integrin-mediated cell-matrix interaction in physiological and pathological blood vessel formation.
Journal: Journal of oncology 20120101
Title: Integrin inhibitors as a therapeutic agent for ovarian cancer.
Journal: Journal of oncology 20120101
Title: Targeting strategies for multifunctional nanoparticles in cancer imaging and therapy.
Journal: Theranostics 20120101
Title: Deciphering the Multifaceted Relationship between Oncolytic Viruses and Natural Killer Cells.
Journal: Advances in virology 20120101
Title: MGMT promoter methylation in gliomas-assessment by pyrosequencing and quantitative methylation-specific PCR.
Journal: Journal of translational medicine 20120101
Title: Methodology for Anti-Gene Anti-IGF-I Therapy of Malignant Tumours.
Journal: Chemotherapy research and practice 20120101
Title: RGD-conjugated gold nanorods induce radiosensitization in melanoma cancer cells by downregulating α(v)β₃ expression.
Journal: International journal of nanomedicine 20120101
Title: Fibronectin matrix-mediated cohesion suppresses invasion of prostate cancer cells.
Journal: BMC cancer 20120101
Title: Prostaglandins in cancer cell adhesion, migration, and invasion.
Journal: International journal of cell biology 20120101
Title: Integrins and their extracellular matrix ligands in lymphangiogenesis and lymph node metastasis.
Journal: International journal of cell biology 20120101
Title: Novel therapies in glioblastoma.
Journal: Neurology research international 20120101
Title: Current trends in targeted therapies for glioblastoma multiforme.
Journal: Neurology research international 20120101
Title: Vitronectin increases vascular permeability by promoting VE-cadherin internalization at cell junctions.
Journal: PloS one 20120101
Title: Combination of RGD compound and low-dose paclitaxel induces apoptosis in human glioblastoma cells.
Journal: PloS one 20120101
Title: Current knowledge on pancreatic cancer.
Journal: Frontiers in oncology 20120101
Title: Cilengitide treatment for malignant glioma: current status and future direction.
Journal: Neurologia medico-chirurgica 20120101
Title: Cilengitide (EMD 121974, NSC 707544) in asymptomatic metastatic castration resistant prostate cancer patients: a randomized phase II trial by the prostate cancer clinical trials consortium.
Journal: Investigational new drugs 20111201
Title: Cilengitide: a prototypic integrin inhibitor for the treatment of glioblastoma and other malignancies.
Journal: Genes & cancer 20111201
Title: Cilengitide inhibits metastatic bone colonization in a nude rat model.
Journal: Oncology reports 20111001
Title: Treatment of high-grade glioma in children and adolescents.
Journal: Neuro-oncology 20111001
Title: [The inhibitor of integrins Cilengitide: a new active drug in neuro-oncology].
Journal: Bulletin du cancer 20111001
Title: Increasing αvβ3 selectivity of the anti-angiogenic drug cilengitide by N-methylation.
Journal: Angewandte Chemie (International ed. in English) 20110926
Title: Impact of therapy on quality of life, neurocognitive function and their correlates in glioblastoma multiforme: a review.
Journal: Journal of neuro-oncology 20110901
Title: Cilengitide induces autophagy-mediated cell death in glioma cells.
Journal: Neuro-oncology 20110801
Title: Advances in MRI assessment of gliomas and response to anti-VEGF therapy.
Journal: Current neurology and neuroscience reports 20110601
Title: Radiation-induced modifications of the tumor microenvironment promote metastasis.
Journal: Bulletin du cancer 20110601
Title: Pathway inhibition: emerging molecular targets for treating glioblastoma.
Journal: Neuro-oncology 20110601
Title: Phase I/II trial of cilengitide with cetuximab, cisplatin and 5-fluorouracil in recurrent and/or metastatic squamous cell cancer of the head and neck: findings of the phase I part.
Journal: British journal of cancer 20110524
Title: Cilengitide inhibits progression of experimental breast cancer bone metastases as imaged noninvasively using VCT, MRI and DCE-MRI in a longitudinal in vivo study.
Journal: International journal of cancer 20110515
Title: Isthmin exerts pro-survival and death-promoting effect on endothelial cells through alphavbeta5 integrin depending on its physical state.
Journal: Cell death & disease 20110501
Title: Recurrent high-grade glioma: a diagnostic and therapeutic challenge.
Journal: Expert review of neurotherapeutics 20110401
Title: Glioblastoma: changing expectations?
Journal: Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico 20110401
Title: Cilengitide: an RGD pentapeptide ανβ3 and ανβ5 integrin inhibitor in development for glioblastoma and other malignancies.
Journal: Future oncology (London, England) 20110301
Title: Angiogenesis and invasion in glioma.
Journal: Brain tumor pathology 20110201
Title: Antiangiogenic agents in the treatment of recurrent or newly diagnosed glioblastoma: analysis of single-agent and combined modality approaches.
Journal: Radiation oncology (London, England) 20110101
Title: Evaluation of the anti-angiogenic properties of the new selective αVβ3 integrin antagonist RGDechiHCit.
Journal: Journal of translational medicine 20110101
Title: Vaccines targeting the neovasculature of tumors.
Journal: Vascular cell 20110101
Title: Integrin αvβ3-targeted gold nanoshells augment tumor vasculature-specific imaging and therapy.
Journal: International journal of nanomedicine 20110101
Title: A meta-analysis of gemcitabine containing chemotherapy for locally advanced and metastatic pancreatic adenocarcinoma.
Journal: Journal of hematology & oncology 20110101
Title: Evaluation of treatment response of cilengitide in an experimental model of breast cancer bone metastasis using dynamic PET with 18F-FDG.
Journal: Hellenic journal of nuclear medicine 20110101
Title: Why integrin as a primary target for imaging and therapy.
Journal: Theranostics 20110101
Title: Integrin targeted therapeutics.
Journal: Theranostics 20110101
Title: Integrin targeted delivery of chemotherapeutics.
Journal: Theranostics 20110101
Title: Investigation of In Vivo Targeting Kinetics of α(v)β(3)-Specific Superparamagnetic Nanoprobes by Time-Resolved MRI.
Journal: Theranostics 20110101
Title: Therapeutic targets for bone metastases in breast cancer.
Journal: Breast cancer research : BCR 20110101
Title: Bevacizumab for the treatment of recurrent glioblastoma.
Journal: Clinical Medicine Insights. Oncology 20110101
Title: Novel diagnostic and therapeutic approaches to malignant glioma.
Journal: Swiss medical weekly 20110101
Title: Identification of novel SNPs in glioblastoma using targeted resequencing.
Journal: PloS one 20110101
Title: The role of integrins in glioma biology and anti-glioma therapies.
Journal: Current pharmaceutical design 20110101
Title: Interaction of tumor cells with the microenvironment.
Journal: Cell communication and signaling : CCS 20110101
Title: Targeting ανβ3 and ανβ5 inhibits photon-induced hypermigration of malignant glioma cells.
Journal: Radiation oncology (London, England) 20110101
Title: Integrins and their ligands in rheumatoid arthritis.
Journal: Arthritis research & therapy 20110101
Title: Inhibitors of Glioma Growth that Reveal the Tumour to the Immune System.
Journal: Clinical Medicine Insights. Oncology 20110101
Title: New agents targeting angiogenesis in glioblastoma.
Journal: Chemotherapy research and practice 20110101
Title: Molecular targets for radiation oncology in prostate cancer.
Journal: Frontiers in oncology 20110101
Title: Combined modality approaches in the management of adult glioblastoma.
Journal: Frontiers in oncology 20110101
Title: Anti-angiogenic therapies for children with cancer.
Journal: Current cancer drug targets 20101201
Title: 2010: neuro-oncology is moving!
Journal: Current opinion in neurology 20101201
Title: Cilengitide: the first anti-angiogenic small molecule drug candidate design, synthesis and clinical evaluation.
Journal: Anti-cancer agents in medicinal chemistry 20101201
Title: What role should cilengitide have in the treatment of glioblastoma?
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20101120
Title: American Association for Cancer Research Genetics and Biology of Brain Cancers 2009, December 13-15, 2009, San Diego, CA.
Journal: Journal of neuro-oncology 20100901
Title: Targeting integrins in malignant glioma.
Journal: Targeted oncology 20100901
Title: [Angiogenesis inhibition in neurooncology. A very promising therapy strategy for malignant glioma].
Journal: Der Nervenarzt 20100801
Title: Emerging targets in osteoporosis disease modification.
Journal: Journal of medicinal chemistry 20100610
Title: Phase I/IIa study of cilengitide and temozolomide with concomitant radiotherapy followed by cilengitide and temozolomide maintenance therapy in patients with newly diagnosed glioblastoma.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20100601
Title: Integrins as target: first phase III trial launches, but questions remain.
Journal: Journal of the National Cancer Institute 20100519
Title: Survival of patients with newly diagnosed glioblastoma treated with radiation and temozolomide in research studies in the United States.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research 20100415
Title: Interplay between cell adhesion and growth factor receptors: from the plasma membrane to the endosomes.
Journal: Cell and tissue research 20100101
Title: Integrins in cancer: biological implications and therapeutic opportunities.
Journal: Nature reviews. Cancer 20100101
Title: BCNU for recurrent glioblastoma multiforme: efficacy, toxicity and prognostic factors.
Journal: BMC cancer 20100101
Title: Endothelial-Rac1 is not required for tumor angiogenesis unless alphavbeta3-integrin is absent.
Journal: PloS one 20100101
Title: Progress on antiangiogenic therapy for patients with malignant glioma.
Journal: Journal of oncology 20100101
Title: Antiangiogenic therapy and mechanisms of tumor resistance in malignant glioma.
Journal: Journal of oncology 20100101
Title: Tumor angiogenesis: insights and innovations.
Journal: Journal of oncology 20100101
Title: Vicrostatin - an anti-invasive multi-integrin targeting chimeric disintegrin with tumor anti-angiogenic and pro-apoptotic activities.
Journal: PloS one 20100101
Title: Mesenchymal migration as a therapeutic target in glioblastoma.
Journal: Journal of oncology 20100101
Title: The potential of nanomedicine therapies to treat neovascular disease in the retina.
Journal: Journal of angiogenesis research 20100101
Title: Cilengitide modulates attachment and viability of human glioma cells, but not sensitivity to irradiation or temozolomide in vitro.
Journal: Neuro-oncology 20091201
Title: alphavbeta3 Integrin-targeting Arg-Gly-Asp (RGD) peptidomimetics containing oligoethylene glycol (OEG) spacers.
Journal: Journal of medicinal chemistry 20091126
Title: Pharmacological inhibition of integrin alphavbeta3 aggravates experimental liver fibrosis and suppresses hepatic angiogenesis.
Journal: Hepatology (Baltimore, Md.) 20091101
Title: Small molecule integrin antagonists in cancer therapy.
Journal: Mini reviews in medicinal chemistry 20091001
Title: Ligands for mapping alphavbeta3-integrin expression in vivo.
Journal: Accounts of chemical research 20090721
Title: Will integrin inhibitors have proangiogenic effects in the clinic?
Journal: Nature medicine 20090701
Title: Radiation sensitization of glioblastoma by cilengitide has unanticipated schedule-dependency.
Journal: International journal of cancer 20090601
Title: A complex extracellular sphingomyelinase of Pseudomonas aeruginosa inhibits angiogenesis by selective cytotoxicity to endothelial cells.
Journal: PLoS pathogens 20090501
Title: Cilengitide: does it really represent a new targeted therapy for recurrent glioblastoma?
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20090410
Title: Morpholine-based RGD-cyclopentapeptides as alphavbeta3/alphavbeta5 integrin ligands: role of configuration towards receptor binding affinity.
Journal: Bioorganic & medicinal chemistry 20090215
Title: The integrin antagonist cilengitide activates alphaVbeta3, disrupts VE-cadherin localization at cell junctions and enhances permeability in endothelial cells.
Journal: PloS one 20090101
Title: Current available therapies and future directions in the treatment of malignant gliomas.
Journal: Biologics : targets & therapy 20090101
Title: Targeted therapy in the treatment of malignant gliomas.
Journal: OncoTargets and therapy 20090101
Title: New therapies for recurrent glioblastomas.
Journal: F1000 medicine reports 20090101
Title: Critical appraisal of temozolomide formulations in the treatment of primary brain tumors: patient considerations.
Journal: Cancer management and research 20090101
Title: Randomized phase II study of cilengitide, an integrin-targeting arginine-glycine-aspartic acid peptide, in recurrent glioblastoma multiforme.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20081201
Title: Valproic acid related idiosyncratic drug induced hepatotoxicity in a glioblastoma patient treated with temozolomide.
Journal: Acta neurologica Belgica 20081201
Title: Therapeutic application of noncytotoxic molecular targeted therapy in gliomas: growth factor receptors and angiogenesis inhibitors.
Journal: The oncologist 20080901
Title: Oncolytic HSV-1 infection of tumors induces angiogenesis and upregulates CYR61.
Journal: Molecular therapy : the journal of the American Society of Gene Therapy 20080801
Title: Cilengitide: an integrin-targeting arginine-glycine-aspartic acid peptide with promising activity for glioblastoma multiforme.
Journal: Expert opinion on investigational drugs 20080801
Title: In vitro sensitivity testing of minimally passaged and uncultured gliomas with TRAIL and/or chemotherapy drugs.
Journal: British journal of cancer 20080722
Title: Gateways to clinical trials.
Journal: Methods and findings in experimental and clinical pharmacology 20080501
Title: Synthesis, SAR and in vitro evaluation of new cyclic Arg-Gly-Asp pseudopentapeptides containing a s-cis peptide bond as integrin alphavbeta3 and alphavbeta5 ligands.
Journal: Bioorganic & medicinal chemistry 20080415
Title: The integrin antagonist cilengitide increases the antitumor activity of temozolomide against malignant melanoma.
Journal: Oncology reports 20080401
Title: Discovery of subnanomolar arginine-glycine-aspartate-based alphaVbeta3/alphaVbeta5 integrin binders embedding 4-aminoproline residues.
Journal: Journal of medicinal chemistry 20080327
Title: Phase I clinical trial of cilengitide in children with refractory brain tumors: Pediatric Brain Tumor Consortium Study PBTC-012.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20080220
Title: Surgical impact on brain tumor invasion: a physical perspective.
Journal: Annals of surgical innovation and research 20080101
Title: Novel therapies in genitourinary cancer: an update.
Journal: Journal of hematology & oncology 20080101
Title: [Cilengitide: a new weapon against glioblastoma?].
Journal: Tumori 20080101
Title: Cilengitide induces cellular detachment and apoptosis in endothelial and glioma cells mediated by inhibition of FAK/src/AKT pathway.
Journal: Journal of experimental & clinical cancer research : CR 20080101
Title: The role of integrins in cancer and the development of anti-integrin therapeutic agents for cancer therapy.
Journal: Perspectives in medicinal chemistry 20080101
Title: 2007 EORTC-NCI-ASCO annual meeting: molecular markers in cancer.
Journal: Ecancermedicalscience 20080101
Title: Diffuse glioma growth: a guerilla war.
Journal: Acta neuropathologica 20071101
Title: Chemoradiotherapy in malignant glioma: standard of care and future directions.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20070910
Title: Tumor angiogenic endothelial cell targeting by a novel integrin-targeted nanoparticle.
Journal: International journal of nanomedicine 20070901
Title: American Society of Clinical Oncology--43rd annual meeting. Research into therapeutics: Part 4.
Journal: IDrugs : the investigational drugs journal 20070801
Title: Assessment of the biological and pharmacological effects of the alpha nu beta3 and alpha nu beta5 integrin receptor antagonist, cilengitide (EMD 121974), in patients with advanced solid tumors.
Journal: Annals of oncology : official journal of the European Society for Medical Oncology 20070801
Title: Cilengitide inhibits proliferation and differentiation of human endothelial progenitor cells in vitro.
Journal: Biochemical and biophysical research communications 20070615
Title: Integrin inhibitors reaching the clinic.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20070501
Title: Phase I and correlative biology study of cilengitide in patients with recurrent malignant glioma.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20070501
Title: Identification of novel short chain 4-substituted indoles as potent alphavbeta3 antagonist using structure-based drug design.
Journal: European journal of medicinal chemistry 20070301
Title: Design and chemical synthesis of integrin ligands.
Journal: Methods in enzymology 20070101
Title: Gateways to clinical trials.
Journal: Methods and findings in experimental and clinical pharmacology 20070101
Title: Effect of the angiogenesis inhibitor Cilengitide (EMD 121974) on glioblastoma growth in nude mice.
Journal: Neurosurgery 20061201
Title: Anti-angiogenic cancer therapy based on integrin alphavbeta3 antagonism.
Journal: Anti-cancer agents in medicinal chemistry 20060901
Title: Integrin alpha v beta 3 antagonist Cilengitide enhances efficacy of radiotherapy in endothelial cell and non-small-cell lung cancer models.
Journal: International journal of radiation oncology, biology, physics 20060801
Title: [Advances in the study of the integrin alpha(v) beta3 antagonists].
Journal: Yao xue xue bao = Acta pharmaceutica Sinica 20060701
Title: Phase 1 trial of the antiangiogenic peptide ATN-161 (Ac-PHSCN-NH(2)), a beta integrin antagonist, in patients with solid tumours.
Journal: British journal of cancer 20060605
Title: Incorporation of the unusual C(alpha)-fluoroalkylamino acids into cyclopeptides: synthesis of arginine-glycine-aspartate (RGD) analogues and study of their conformational and biological behavior.
Journal: Journal of medicinal chemistry 20060309
Title: Integrins: molecular targets in cancer therapy.
Journal: Current oncology reports 20060301
Title: Phase II evaluations of cilengitide in asymptomatic patients with androgen-independent prostate cancer: scientific rationale and study design.
Journal: Clinical genitourinary cancer 20060301
Title: A randomized multi-center phase II trial of the angiogenesis inhibitor Cilengitide (EMD 121974) and gemcitabine compared with gemcitabine alone in advanced unresectable pancreatic cancer.
Journal: BMC cancer 20060101
Title: Grafting aminocyclopentane carboxylic acids onto the RGD tripeptide sequence generates low nanomolar alphaVbeta3/alphaVbeta5 integrin dual binders.
Journal: Journal of medicinal chemistry 20051201
Title: [Inhibition of cellular adhesion and invasion in gliomas].
Journal: Nihon rinsho. Japanese journal of clinical medicine 20050901
Title: Epidermal growth factor receptor blockade mediates smooth muscle cell apoptosis and improves survival in rats with pulmonary hypertension.
Journal: Circulation 20050719
Title: Noninvasive visualization of the activated alphavbeta3 integrin in cancer patients by positron emission tomography and [18F]Galacto-RGD.
Journal: PLoS medicine 20050301
Title: Clinical trials referral resource. Current clinical trials of cilengitide, an alpha(v) antagonist in clinical development as an anticancer agent.
Journal: Oncology (Williston Park, N.Y.) 20041201
Title: Integrins: roles in cancer development and as treatment targets.
Journal: British journal of cancer 20040209
Title: Cilengitide (EMD 121974) arrests the growth of a heavily pretreated highly vascularised head and neck tumour.
Journal: Oral oncology 20040201
Title: Angiogenesis inhibitors in clinical development; where are we now and where are we going?
Journal: British journal of cancer 20040112
Title: Alpha v integrin inhibitors and cancer therapy.
Journal: Current opinion in investigational drugs (London, England : 2000) 20030601
Title: Cilengitide Merck.
Journal: Current opinion in investigational drugs (London, England : 2000) 20030601
Title: Phase I and pharmacokinetic study of continuous twice weekly intravenous administration of Cilengitide (EMD 121974), a novel inhibitor of the integrins alphavbeta3 and alphavbeta5 in patients with advanced solid tumours.
Journal: European journal of cancer (Oxford, England : 1990) 20030501
Title: Gateways to clinical trials.
Journal: Methods and findings in experimental and clinical pharmacology 20030101
Title: alphav beta 3 and alphav beta 5 integrin antagonists inhibit angiogenesis in vitro.
Journal: Angiogenesis 20030101
Title: Divalent cations and the relationship between alphaA and betaA domains in integrins.
Journal: Biochemical pharmacology 20020901
Title: Cilengitide targeting of alpha(v)beta(3) integrin receptor synergizes with radioimmunotherapy to increase efficacy and apoptosis in breast cancer xenografts.
Journal: Cancer research 20020801
Title: Crystal structure of the extracellular segment of integrin alpha Vbeta3 in complex with an Arg-Gly-Asp ligand.
Journal: Science (New York, N.Y.) 20020405
Title: Nanomolar small molecule inhibitors for alphav(beta)6, alphav(beta)5, and alphav(beta)3 integrins.
Journal: Journal of medicinal chemistry 20020227
Title: Snake venom protein paralyzes cancer cells.
Journal: Journal of the National Cancer Institute 20010221
Title: Preferential susceptibility of brain tumors to the antiangiogenic effects of an alpha(v) integrin antagonist.
Journal: Neurosurgery 20010101
Title: Hariharan S, et al. Assessment of the biological and pharmacological effects of the alpha nu beta3 and alpha nu beta5 integrinreceptor antagonist, Cilengitide (EMD 121974), in patients with advanced solid tumors. Ann Oncol. 2007 Aug;18(8):1400-7.
